Outlook Therapeutics (OTLK) grants 286,734 options at $1.04

Q: What did Outlook Therapeutics (OTLK) report on this Form 4?

Director Julia A. Haller was granted 286,734 stock options at $1.04 on 10/01/2025 and 58,648 options at $1.06 on 10/03/2025.

Q: When do the options vest for Julia A. Haller?

The 286,734 options vest in full on 10/01/2026 with continued service; the 58,648 options vest in four equal quarterly installments, fully vesting on 9/30/2026.

Q: Were any cash fees exchanged for equity?

Yes, the 58,648 options were granted under the 2024 Plan in lieu of $55,000 cash fees under the non-employee director compensation policy.

Q: What are the exercise prices and expirations?

The 286,734 options have an exercise price of $1.04 and a 10/01/2035 expiration; the 58,648 options have an exercise price of $1.06 and a 10/03/2035 expiration.

Outlook Therapeutics director Julia A. Haller received two stock option grants reported on 10/01/2025 and 10/03/2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Outlook Therapeutics director Julia A. Haller received two stock option grants reported on 10/01/2025 and 10/03/2025. The first grant is for 286,734 options with an exercise price of $1.04 that vest in full on 10/01/2026 subject to continued service and acceleration on a defined Change in Control. The second grant is for 58,648 options at $1.06, issued in lieu of $55,000 in cash fees and vesting in four equal quarterly installments through 9/30/2026, also subject to service and Change in Control acceleration.

Positive

286,734 options granted at $1.04 (10/01/2025) aligning director incentives with shareholders
58,648 options ($1.06) issued in lieu of $55,000 cash fees, conserving cash

Negative

Option grants create potential dilution of outstanding equity by 345,382 shares if exercised
Vesting is service-based, so accelerated vesting triggers on a Change in Control could accelerate dilution

Insider Trade Summary

Grant/Award: 345,382 shares

Grant/Award 2 txns

Insider Haller Julia A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	58,648	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	286,734	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 345,382 contracts (Direct)

Footnotes (2)

F1. This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
F2. The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Outlook Therapeutics (OTLK) report on this Form 4?

Director Julia A. Haller was granted 286,734 stock options at $1.04 on 10/01/2025 and 58,648 options at $1.06 on 10/03/2025.

When do the options vest for Julia A. Haller?

The 286,734 options vest in full on 10/01/2026 with continued service; the 58,648 options vest in four equal quarterly installments, fully vesting on 9/30/2026.

Were any cash fees exchanged for equity?

Yes, the 58,648 options were granted under the 2024 Plan in lieu of $55,000 cash fees under the non-employee director compensation policy.

What are the exercise prices and expirations?

The 286,734 options have an exercise price of $1.04 and a 10/01/2035 expiration; the 58,648 options have an exercise price of $1.06 and a 10/03/2035 expiration.

Is there any acceleration feature on these awards?

Yes, both option grants are subject to acceleration upon a defined Change in Control, conditioned on continued service immediately prior to such event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 10/03/2025 - 08:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Haller Julia A

(Last)

(First)

(Middle)

C/O OUTLOOK THERAPEUTICS, INC.

111 S. WOOD AVE, UNIT #100

(Street)

ISELIN

08830

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Outlook Therapeutics, Inc. [ OTLK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.04	10/01/2025		A		286,734		⁽¹⁾	10/01/2035	Common Stock	286,734	$0	286,734	D
Stock Option (Right to Buy)	$1.06	10/03/2025		A		58,648		⁽²⁾	10/03/2035	Common Stock	58,648	$0	58,648	D

Explanation of Responses:

1. This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

2. The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

	/s/Lawrence A. Kenyon, Attorney-in-Fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR